Company intelligence / Profile preview

Legekontor

Somerset, New Jersey, United Stateszoominfo.com ↗

Ownership: Private
Employees: ~2600
Development stage: Commercial

Overview

Legend Biotech is a global leader in developing novel cellular immunotherapies. Its lead product, ciltacabtagene autoleucel ("cilta-cel", marketed as Carvykti®), is an FDA-approved BCMA-directed CAR-T for multiple myeloma with strong five-year survival data. The pipeline includes additional autologous and allogeneic programs targeting hematologic malignancies and solid tumors at various clinical stages.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyAllogeneic CAR-T cell therapyAllogeneic CAR-NK cell therapyCell therapy
Industry: Biotech

Partnerships

Janssen Biotech (Johnson & Johnson) – co-development/commercialization of cilta-celNovartis Pharma AG – license agreement for Dll3-targeting therapies

Beyond the preview

Go deeper on Legekontor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legekontor.

Explore the full profile